-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $23

Benzinga·04/09/2025 18:41:32
Listen to the news
Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $28 to $23.